• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MorphoSys AG - American Depositary Shares (NQ:MOR)

18.96 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MorphoSys AG - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
August 27, 2024
Via ACCESSWIRE
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders
July 17, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
July 12, 2024
From MorphoSys AG
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders
July 08, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
March 07, 2024
Via ACCESSWIRE
MorphoSys AG (NASDAQ: MOR) Near the Top of Equities by Percentage Gain on 2/5
February 05, 2024
Via Investor Brand Network
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders
June 29, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders
June 20, 2024
From Halper Sadeh LLC
Via Business Wire
News headline image
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
June 20, 2024
From MorphoSys AG
Via Business Wire
News headline image
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
June 19, 2024
Via ACCESSWIRE
MorphoSys AG (NASDAQ: MOR) Leading the Way in Monday Trading Based on Percentage Gain
December 11, 2023
Via Investor Brand Network
News headline image
Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
November 09, 2023
Via ACCESSWIRE
News headline image
MorphoSys AG Reports First Quarter 2024 Financial Results
April 29, 2024
From MorphoSys AG
Via Business Wire
News headline image
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
April 24, 2024
Via ACCESSWIRE
News headline image
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
April 11, 2024
From MorphoSys AG
Via Business Wire
News headline image
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
April 11, 2024
Via ACCESSWIRE
News headline image
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
March 21, 2024
Via ACCESSWIRE
News headline image
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 13, 2024
From MorphoSys AG
Via Business Wire
News headline image
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
February 05, 2024
Via ACCESSWIRE
News headline image
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
January 29, 2024
Via ACCESSWIRE
News headline image
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 07, 2024
Via ACCESSWIRE
News headline image
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
December 10, 2023
From MorphoSys AG
Via Business Wire
News headline image
Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
November 20, 2023
Via ACCESSWIRE
News headline image
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
November 20, 2023
From MorphoSys AG
Via Business Wire
News headline image
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
November 15, 2023
From MorphoSys AG
Via Business Wire
News headline image
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
November 02, 2023
Via ACCESSWIRE
News headline image
MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
October 25, 2023
Via ACCESSWIRE
News headline image
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
September 12, 2023
Via ACCESSWIRE
News headline image
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
August 09, 2023
From MorphoSys AG
Via Business Wire
News headline image
MorphoSys AG Reports First Quarter 2023 Financial Results
May 03, 2023
From MorphoSys AG
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap